CombiGene has entered into an exclusive collaboration and licensing agreement with Spark Therapeutics regarding CG01, CombiGene's gene therapy developed for the treatment of drug-resistant focal epilepsy. Under the terms of the agreement, CombiGene is eligible to receive up to USD 328.5 million excluding royalties, with USD 8.5 million upon signing, as well as up to USD 50 million at several preclinical and clinical milestones.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.77 SEK | +0.27% | -2.08% | +40.15% |
Mar. 13 | CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries | CI |
Feb. 21 | Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI). | CI |
1st Jan change | Capi. | |
---|---|---|
+40.15% | 6.81M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- COMBI Stock
- News CombiGene AB
- CombiGene in Billion-Dollar Deal with Spark Therapeutics